No Group two equivalent: The UK hasn't executed a blanket ban on compounding specific peptides just like the FDA's 2024 determination. Having said that, the MHRA can and does consider action in opposition to specials suppliers who produce goods with no enough scientific justification.The real key difference is the route of administration and therap